两周与八周延长暴露疗法及当前中心疗法对军人PTSD症状严重程度的影响:一项随机临床试验
该随机临床试验纳入370名患有PTSD的现役军人,比较集中延长暴露疗法(2周10次)、间隔延长暴露疗法(8周10次)、当前中心疗法和最小接触对照对PTSD严重程度的影响。主要结局显示,集中疗法在治疗后2周优于最小接触对照,且不劣于间隔疗法;间隔疗法与当前中心疗法无显著差异。所有疗法的症状减轻幅度相对有限。
要点
- 集中延长暴露疗法(2周10次)在治疗后2周对PTSD症状的改善优于最小接触对照。
- 集中延长暴露疗法在治疗后2周和12周不劣于间隔延长暴露疗法(8周10次)。
- 间隔延长暴露疗法与当前中心疗法在治疗后PTSD症状改善上无显著差异。
核心结论
- 在现役军人PTSD患者中,集中延长暴露疗法(2周10次)在2周随访时比最小接触对照更有效地降低PTSD症状严重程度,且不劣于间隔延长暴露疗法(8周10次)。
- 间隔延长暴露疗法与当前中心疗法在治疗后PTSD症状严重程度上无显著差异。
- 所有疗法对PTSD症状严重程度的减轻相对有限,提示需要进一步研究以确定这些发现的临床重要性。
研究设计与样本
- 随机临床试验,2011年1月至2016年7月在德克萨斯州胡德堡开展,纳入370名从伊拉克、阿富汗或两地返回的患有PTSD的军人。
- 干预分组:集中延长暴露疗法(n=110;2周内10次)、间隔延长暴露疗法(n=109;8周内10次)、当前中心疗法(n=107;8周内10次)、最小接触对照(n=40;每周一次电话,共4周)。
- 最终随访截至2016年7月11日;366名参与者纳入分析(平均年龄32.7岁[SD 7.3],女性44名[12.0%],基线PSS-I平均分25.49[6.36]),216名(59.0%)完成研究。
关键数值与推荐
- 主要结局为访谈者评估的PTSD症状严重程度,采用PTSD症状量表-访谈(PSS-I;范围0-51,分数越高表示PTSD越严重;MCID为3.18)。
- 间隔疗法 vs 当前中心疗法的疗效在治疗后评估。
临床怎么用
- 对于现役军人PTSD,集中延长暴露疗法(2周10次)可在短期内(2周)显著降低PTSD症状严重程度,且效果不劣于8周间隔疗法。
- 间隔延长暴露疗法与当前中心疗法在改善PTSD症状严重程度上无显著差异。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Effective and efficient treatment is needed for posttraumatic stress disorder (PTSD) in active duty military personnel. OBJECTIVE: To examine the effects of massed prolonged exposure therapy (massed therapy), spaced prolonged exposure therapy (spaced therapy), present-centered therapy (PCT), and a minimal-contact control (MCC) on PTSD severity. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at Fort Hood, Texas, from January 2011 through July 2016 and enrolling 370 military personnel with PTSD who had returned from Iraq, Afghanistan, or both. Final follow-up was July 11, 2016. INTERVENTIONS: Prolonged exposure therapy, cognitive behavioral therapy involving exposure to trauma memories/reminders, administered as massed therapy (n = 110; 10 sessions over 2 weeks) or spaced therapy (n = 109; 10 sessions over 8 weeks); PCT, a non-trauma-focused therapy involving identifying/discussing daily stressors (n = 107; 10 sessions over 8 weeks); or MCC, telephone calls from therapists (n = 40; once weekly for 4 weeks). MAIN OUTCOMES AND MEASURES: Outcomes were assessed before and after treatment and at 2-week, 12-week, and 6-month follow-up. Primary outcome was interviewer-assessed PTSD symptom severity, measured by the PTSD Symptom Scale-Interview (PSS-I; range, 0-51; higher scores indicate greater PTSD severity; MCID, 3.18), used to assess efficacy of massed therapy at 2 weeks posttreatment vs MCC at week 4; noninferiority of massed therapy vs spaced therapy at 2 weeks and 12 weeks posttreatment (noninferiority margin, 50% [2.3 points on PSS-I, with 1-sided α = .05]); and efficacy of spaced therapy vs PCT at posttreatment. RESULTS: Among 370 randomized participants, data were analyzed for 366 (mean age, 32.7 [SD, 7.3] years; 44 women [12.0%]; mean baseline PSS-I score, 25.49 [6.36]), and 216 (59.0%) completed the study. At 2 weeks posttreatment, mean PSS-I score was 17.62 (mean decrease from baseline, 7.13) for massed therapy and 21.41 (mean decrease, 3.43) for MCC (difference in decrease, 3.70 [95% CI,0.72 to 6.68]; P = .02). At 2 weeks posttreatment, mean PSS-I score was 18.03 for spaced therapy (decrease, 7.29; difference in means vs massed therapy, 0.79 [1-sided 95% CI, -∞ to 2.29; P = .049 for noninferiority]) and at 12 weeks posttreatment was 18.88 for massed therapy (decrease, 6.32) and 18.34 for spaced therapy (decrease, 6.97; difference, 0.55 [1-sided 95% CI, -∞ to 2.05; P = .03 for noninferiority]). At posttreatment, PSS-I scores for PCT were 18.65 (decrease, 7.31; difference in decrease vs spaced therapy, 0.10 [95% CI, -2.48 to 2.27]; P = .93). CONCLUSIONS AND RELEVANCE: Among active duty military personnel with PTSD, massed therapy (10 sessions over 2 weeks) reduced PTSD symptom severity more than MCC at 2-week follow-up and was noninferior to spaced therapy (10 sessions over 8 weeks), and there was no significant difference between spaced therapy and PCT. The reductions in PTSD symptom severity with all treatments were relatively modest, suggesting that further research is needed to determine the clinical importance of these findings. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01049516.
引用
- Foa EB, McLean CP, Zang Y, et al. Effect of Prolonged Exposure Therapy Delivered Over 2 Weeks vs 8 Weeks vs Present-Centered Therapy on PTSD Symptom Severity in Military Personnel: A Randomized Clinical Trial. JAMA. 2018. PMID: 29362795. doi:10.1001/jama.2017.21242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。